<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03541486</url>
  </required_header>
  <id_info>
    <org_study_id>XACT-PANC-2</org_study_id>
    <nct_id>NCT03541486</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients</brief_title>
  <acronym>XACT-PANC-2</acronym>
  <official_title>XACT-Pancreas 2: Pharmacological Ascorbate, Gemcitabine, and Radiation Therapy for Pancreatic Cancer, Phase 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph J. Cullen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Holden Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 study testing the initial efficacy of adding pharmacological ascorbate
      (vitamin C) to standard radiation and chemotherapy for treatment of pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 2 study is designed to determine the efficacy of adding pharmacological ascorbate
      (vitamin C) to standard chemoradiation. The ascorbate is infused before, during, and after
      the external beam radiation therapy treatment. Each ascorbate infusion is 75 grams (roughly
      the same amount of vitamin C from 1,000 oranges).

      For patients eligible for this trial, standard treatment for their cancer includes radiation
      therapy combined with weekly gemcitabine (a chemotherapy).

      Participants will:

        -  decide if they want to receive the investigational treatment (pharmacological ascorbate
           plus gemcitabine plus radiation) or standard treatment only (gemcitabine plus radiation)

        -  receive pharmacological ascorbate intravenously ascorbate during their daily radiation
           therapy treatments, if they choose the investigational treatment.

        -  receive gemcitabine (a chemotherapy) once a week for up to 6 weeks of therapy (all
           participants)

        -  receive radiation treatments are given once a day, Monday through Friday (all
           participants).

        -  have routine doctor's visits and be asked about any side effects they are experiencing
           (all participants).

      This is a phase 2 study to determine the effect, if any, adding pharmacological ascorbate
      will have on standard therapy for pancreatic cancer. The study will also record any side
      effects of adding ascorbate to standard therapy. Once the patient completes radiation, the
      ascorbate infusions are also completed. However, the patient will need to return for regular
      follow-up care at University of Iowa.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2029</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The trial participant will determine their treatment assignment (standard vs. experimental)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Radiologic measurements will be completed by a reviewer blinded to treatment assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 10 years post treatment</time_frame>
    <description>The study will determine the time (calculated in months) between study day 1 and death from any cause. After 10 years post-treatment, dates will be censored to date of last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>12 and 24 months post-treatment</time_frame>
    <description>Objective response rate is defined as the number of partial response and complete response outcomes in the intent-to-treat population (partial and complete response are defined using the Response Evaluation Criteria in Solid Tumors (RECIST)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 10 years post-treatment</time_frame>
    <description>From radiation day 1 to documented disease progression in CT imaging as described by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Measured in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity over time (ToxT)</measure>
    <time_frame>Treatment day 1 to 30 days post-treatment</time_frame>
    <description>Toxicity over time will be assessed by summarizing treatment emergent adverse events by system organ class and/or preferred term, type of adverse event, and severity. Elapsed days of toxicity will be summarized.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploration of patient reported outcomes during combined therapy [quantitative string]</measure>
    <time_frame>During treatment phase (approximately 7 weeks)</time_frame>
    <description>Patient completed quality of life (EORTC QLQ C-30 form) and symptom score forms (NCI's PRO-CTCAE) collected weekly.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploration of patient reported outcomes during combined therapy [qualitative string]</measure>
    <time_frame>During treatment phase and up to 60 days after completing treatment</time_frame>
    <description>Semi-structure focus group or one-on-one interviews for thematic analysis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreatic Neoplasm</condition>
  <arm_group>
    <arm_group_label>Investigational Therapy (ASC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 grams of pharmacological ascorbate, daily (M-F) 600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Therapy (ChemoRT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbate</intervention_name>
    <description>75 gram infusion daily (M-F) on days when radiation therapy is administered</description>
    <arm_group_label>Investigational Therapy (ASC)</arm_group_label>
    <other_name>Ascor L 500</other_name>
    <other_name>Pharmacological ascorbate</other_name>
    <other_name>Vitamin C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>600 mg/m2 once weekly for 6 weeks</description>
    <arm_group_label>Investigational Therapy (ASC)</arm_group_label>
    <arm_group_label>Standard Therapy (ChemoRT)</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.</description>
    <arm_group_label>Investigational Therapy (ASC)</arm_group_label>
    <arm_group_label>Standard Therapy (ChemoRT)</arm_group_label>
    <other_name>Volumetric Arc Therapy (VMAT)</other_name>
    <other_name>External beam radiation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible to participate in this study, an individual must meet ALL of the following
        criteria:

          -  Ability and willingness to provide informed consent (power of attorney and legally
             authorized representatives are not accepted for informed consent)

          -  Stated willingness to comply with all study procedures and availability for duration
             of the study

          -  At least 18 years of age

          -  Histologic or cytologic diagnosis of pancreatic adenocarcinoma

          -  Recommended to receive gemcitabine-based chemoradiation

          -  Good performance status (ECOG of 0, 1, or 2; KPS of &gt; 50)

          -  No other active malignancy that requires immediate treatment. Low grown concurrent
             cancers are acceptable with the appropriate documentation from the treating
             oncologists for that additional primary disease.

          -  Not experiencing an uncontrolled illness such as infection requiring inpatient
             admission, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or any other condition that would limit compliance with the study
             requirements or unacceptably increase risk to the participant (as determined by study
             team members).

          -  Agree to abstain from alcohol and specified over the counter supplements during study
             treatment

        Exclusion Criteria:

        An individual who meets any of the following criteria will be excluded from participating
        in this study:

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency

          -  HIV positive individuals requiring anti-retroviral drug therapy (high-dose ascorbate
             is known to interact with many of these drugs)

          -  Platelet count of &lt;100,000 k/mm3

          -  Prior radiation that would result in field overlap (this will be determined by the
             study's radiation oncologist)

          -  Actively receiving insulin

          -  Other therapy (including radiation therapy) within 2 calendar weeks of study therapy

          -  On any of the following drugs and cannot or will not accept a drug substitution:
             warfarin, flecainide, methadone, amphetamines, quinidine, and chlorpropamide

          -  Other investigational agents (PET or SPECT imaging agents are acceptable)

          -  Other investigational therapy with the intention to treat the disease under study

          -  Pregnancy

          -  Individuals declining to use acceptable birth control during the duration of the study

          -  Lactating women who decline to discontinue breastfeeding their child (women may
             withhold breast feeding and resume under the direction of their medical oncologist
             after completion of study)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph J. Cullen, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph J. Cullen, MD, FACS</last_name>
    <phone>(319) 353-8297</phone>
    <email>joseph-cullen@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bryan G. Allen, MD, PhD</last_name>
    <phone>(319) 356-3693</phone>
    <email>bryan-allen@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sandy Vollstedt, RN, BSN, OCN</last_name>
      <phone>319-353-7143</phone>
      <email>sandy-vollstedt@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Brown, RN, BAN, OCN</last_name>
      <phone>319-384-7912</phone>
      <email>heather-brown@uiowa.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O(2)(â‹…-) and H(2)O(2)-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum in: Cancer Cell. 2017 Aug 14;32(2):268.</citation>
    <PMID>28366679</PMID>
  </reference>
  <reference>
    <citation>Welsh JL, Wagner BA, van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, Cullen JJ. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013 Mar;71(3):765-75. doi: 10.1007/s00280-013-2070-8. Epub 2013 Feb 5.</citation>
    <PMID>23381814</PMID>
  </reference>
  <reference>
    <citation>Doskey CM, Buranasudja V, Wagner BA, Wilkes JG, Du J, Cullen JJ, Buettner GR. Tumor cells have decreased ability to metabolize H(2)O(2): Implications for pharmacological ascorbate in cancer therapy. Redox Biol. 2016 Dec;10:274-284. doi: 10.1016/j.redox.2016.10.010. Epub 2016 Oct 28.</citation>
    <PMID>27833040</PMID>
  </reference>
  <reference>
    <citation>Cieslak JA, Cullen JJ. Treatment of Pancreatic Cancer with Pharmacological Ascorbate. Curr Pharm Biotechnol. 2015;16(9):759-70. Review.</citation>
    <PMID>26201606</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 29, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Joseph J. Cullen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ascorbic acid</keyword>
  <keyword>ascorbate</keyword>
  <keyword>sodium ascorbate</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>radiotherapy, image-guided</keyword>
  <keyword>gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected IPD, including endpoints (OS, ORR, PFS, AE, and PROs), treatment information, and demographics.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Study protocol and consent will be shared after primary completion. Statistical analysis plan will be shared with results reporting. Data are available upon request and will be available for 2 years after the withdraw of the IND.</ipd_time_frame>
    <ipd_access_criteria>An IRB-stamped signed usage agreement will be required in addition to a data sharing agreement between the academic centers. Interested researchers should contact Dr. Cullen or Dr. Allen.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

